1. https://adisinsight.springer.com/
2. https://www.expresspharma.in/pharma-ma-and-venture-capital-deals-reach-33-7-billion-in-jan-2025/
3. https://www.techtarget.com/pharmalifesciences/resources/Mergers-and-acquisitions-in-pharma-and-biotech#:~:text=Mergers%20and%20acquisitions%20in%20pharmaceutical,capabilities%20and%20increase%20market%20competitiveness
4. https://www.ey.com/en_gl/insights/life-sciences/why-licensing-deals-are-a-powerful-source-of-growth-in-life-sciences#:~:text=In%2Dlicensing%20deals%20are%20a,partnerships%20and%20de%2Drisking%20investments.
5. https://www.contractpharma.com/what-drives-mergers-acquisitions-in-the-pharma-industry/#:~:text=In%20conclusion%2C%20M&A%20is%20a,or%20to%20prune%20business%20portfolios.
6. https://www.mckinsey.com/capabilities/strategy-and-corporate-finance/our-insights/whats-behind-the-pharmaceutical-sectors-m-and-a-push
7. https://www.mckinsey.com/capabilities/m-and-a/our-insights/a-new-prescription-for-m-and-a-in-pharma
8. https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-m-and-a-shows-new-signs-of-life
9. https://www.ey.com/en_gl/insights/life-sciences/why-licensing-deals-are-a-powerful-source-of-growth-in-life-sciences#:~:text=In%2Dlicensing%20deals%20are%20a,partnerships%20and%20de%2Drisking%20investments.
10. https://www.fiercepharma.com/pharma/top-10-biopharma-ma-deals-2024#:~:text=Oncology%20remains%20an%20area%20of,metabolic%2C%20the%20Leerink%20team%20said.
11. https://www.mckinsey.com/industries/life-sciences/our-insights/five-ways-biopharma-companies-can-navigate-the-deal-landscape
12. https://www.definitivehc.com/blog/pharma-cost-saving-market-share-strategies#:~:text=Accelerating%20innovation%20in%20biotech%20through,life%2Dsaving%20therapies%20to%20patients.
13. https://www.excedr.com/blog/how-biotech-partnerships-support-research#:~:text=Through%20partnerships%2C%20large%20pharma%20companies,advanced%20technologies%20and%20promising%20therapies.
14. https://tippie.uiowa.edu/news/2025/01/when-pharma-mergers-lead-lower-drug-prices#:~:text=%E2%80%9CCompanies%20that%20make%20generic%20drugs,Business%20and%20study%20co%2Dauthor.
15. https://www.ey.com/en_gl/insights/life-sciences/why-licensing-deals-are-a-powerful-source-of-growth-in-life-sciences#:~:text=In%2Dlicensing%20deals%20are%20a,partnerships%20and%20de%2Drisking%20investments.
16. https://www.contractpharma.com/what-drives-mergers-acquisitions-in-the-pharma-industry/#:~:text=In%20conclusion%2C%20M&A%20is%20a,or%20to%20prune%20business%20portfolios.
17. https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases
18. https://www.leo-pharma.com/media-center/news/2025-gilead-and-leo-pharma-enters-into-strategic-partnership#:~:text=Gilead%20and%20LEO%20Pharma%20Enter%20Into%20Strategic,Formulations%20of%20the%20STAT6%20Program%20in%20Dermatology.
19. https://investors.gilead.com/news/news-details/2025/Gilead-and-LEO-Pharma-Enter-Into-Strategic-Partnership-to-Accelerate-Development-of-Oral-STAT6-Program-With-Potential-in-Multiple-Inflammatory-Diseases/default.aspx#:~:text=This%20transaction%20with%20LEO%20Pharma,About%20Gilead%20Sciences
20. https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-leo-pharma-partner-develop-programs-inflammatory-diseases-2025-01-11/#:~:text=The%20transaction%20is%20expected%20to,Dugar;%20editing%20by%20Diane%20Craft
21. https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases#:~:text=January%2011%2C%202025-,Gilead%20and%20LEO%20Pharma%20Enter%20Into%20Strategic%20Partnership%20to%20Accelerate,STAT6%20Program%20in%20Dermatology%20%2D%2D
22. https://pharmatimes.com/news/gilead-and-leo-pharma-partner-to-develop-oral-stat6-program/#:~:text=Flavius%20Martin%2C%20Executive%20Vice%20President,new%20options%20for%20patients%20worldwide.
23. https://www.biopharmatrend.com/post/1108-gilead-strikes-17b-deal-with-leo-pharma-for-oral-stat6-therapies-in-inflammatory-diseases/#:~:text=Gilead%20Sciences%20has%20announced%20a%20$1.7%20billion,STAT6%20small%2Dmolecule%20inhibitors%20and%20targeted%20protein%20degraders
24. https://www.nature.com/articles/d41573-024-00012-8#:~:text=Despite%20the%20considerable%20drop%20in,to%20Amgen%20for%20$13.4%20billion.
25. https://www.biopharmatrend.com/post/1108-gilead-strikes-17b-deal-with-leo-pharma-for-oral-stat6-therapies-in-inflammatory-diseases/#:~:text=Gilead%20Sciences%20has%20announced%20a%20$1.7%20billion,beyond%20infectious%20diseases%20and%20into%20inflammatory%20conditions.
26. https://www.gilead.com/science/pipeline#:~:text=Overview,care%20for%20life%2Dthreatening%20diseases.
27. https://www.leo-pharma.com/media-center/news/2025-gilead-and-leo-pharma-enters-into-strategic-partnership#:~:text=Gilead%20and%20LEO%20Pharma%20Enter%20Into%20Strategic,Formulations%20of%20the%20STAT6%20Program%20in%20Dermatology.
28. https://investors.gilead.com/news/news-details/2025/Gilead-and-LEO-Pharma-Enter-Into-Strategic-Partnership-to-Accelerate-Development-of-Oral-STAT6-Program-With-Potential-in-Multiple-Inflammatory-Diseases/default.aspx#:~:text=This%20transaction%20with%20LEO%20Pharma,About%20Gilead%20Sciences
29. https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-leo-pharma-partner-develop-programs-inflammatory-diseases-2025-01-11/#:~:text=The%20transaction%20is%20expected%20to,Dugar;%20editing%20by%20Diane%20Craft
30. https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases#:~:text=January%2011%2C%202025-,Gilead%20and%20LEO%20Pharma%20Enter%20Into%20Strategic%20Partnership%20to%20Accelerate,STAT6%20Program%20in%20Dermatology%20%2D%2D
31. https://pharmatimes.com/news/gilead-and-leo-pharma-partner-to-develop-oral-stat6-program/#:~:text=Flavius%20Martin%2C%20Executive%20Vice%20President,new%20options%20for%20patients%20worldwide
32. https://www.biopharmatrend.com/post/1108-gilead-strikes-17b-deal-with-leo-pharma-for-oral-stat6-therapies-in-inflammatory-diseases/#:~:text=Gilead%20Sciences%20has%20announced%20a%20$1.7%20billion,STAT6%20small%2Dmolecule%20inhibitors%20and%20targeted%20protein%20degraders.
33. https://www.globenewswire.com/news-release/2023/09/14/2743494/0/en/Global-Anti-Inflammatory-Drugs-Market-Size-to-Reach-USD-250-08-Billion-in-2030-Emergen-Research.html
34. https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2020-financial-results/#:~:text=Fourth%2DQuarter%202020%20Worldwide%20Sales,Non%2DGAAP%20EPS%20Was%20$5.94
35. https://www.merck.com/news/merck-announces-first-quarter-2025-financial-results/
36. https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2021-financial-results/#:~:text=Fourth%2DQuarter%20and%20Full%2DYear%20Results%20Reflect%20Continued%20Strong%20Business,2022%20Financial%20Outlook
37. https://www.fiercepharma.com/special-reports/top-20-drugs-worldwide-sales-2021
38. https://www.macrotrends.net/stocks/charts/MRK/merck/revenue#:~:text=Merck%20annual%20revenue%20for%202022,a%2021.72%25%20increase%20from%202021.
39. https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2022-financial-results/
40. https://www.statista.com/statistics/272350/revenue-of-merck-and-co/#:~:text=The%20revenue%20of%20Merck%20%26%20Co,traded%20company%20named%20Organon%20%26%20Co.
41. https://www.biospace.com/deals/merck-and-epitopea-join-forces-to-identify-unknown-tumor-antigens#:~:text=Facing%20the%202028%20loss%20of,in%20an%20undisclosed%20solid%20tumor.
42. https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-license-agreement-with-alteogen-for-subcutaneous-formulations-of-multiple-oncology-assets.html
43. https://www.pharmexec.com/view/astrazeneca-acquires-esobiotec-strikes-deal-alteogen-develop-oncology-therapies
44. https://www.fiercepharma.com/pharma/astrazeneca-signs-135b-alteogen-deal-subcutaneous-cancer-drugs-despite-merck-halozyme-patent
45. https://www.pharmaceutical-technology.com/news/astrazeneca-alteogen-platform-technology/#:~:text=AstraZeneca%20has%20entered%20an%20exclusive%20licence%20agreement,develop%20subcutaneous%20formulations%20of%20several%20oncology%20assets.&text=ALT%2DB4%20therapy%20facilitates%20the%20large%2Dvolume%20subcutaneous%20drug,hydrolysation%20of%20hyaluronan%20in%20the%20extracellular%20matrix.
46. https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-license-agreement-with-alteogen-for-subcutaneous-formulations-of-multiple-oncology-assets.html#:~:text=Under%20the%20terms%20of%20the,of%20ALT%2DB4%20to%20AstraZeneca.
47. https://www.pharmtech.com/view/astrazeneca-alteogen-sign-license-agreement-developing-subcutaneous-formulations-oncology-assets
48. https://www.biosb.com/biosb-products/stat6-antibody-rmab-rm473/
49. https://www.affbiotech.com/goods-1899-AF6302-STAT6_Antibody.html
50. https://www.rndsystems.com/target/stat6
51. https://www.sciencedirect.com/science/article/pii/S107476131730568X#:~:text=The%20Transcription%20Factor%20STAT6%20Mediates,of%20Alternatively%20Polarized%20Macrophages%20%2D%20ScienceDirect
52. https://pmc.ncbi.nlm.nih.gov/articles/PMC3876430/#:~:text=Summary,variety%20of%20human%20lung%20diseases.
53. https://www.jacionline.org/article/S0091-6749(24)01029-7/fulltext#:~:text=Signal%20transducer%20and%20activator%20of,widely%20targeted%20in%20asthma%20treatment.
54. https://www.epitopea.com/platform/
55. https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-license-agreement-with-alteogen-for-subcutaneous-formulations-of-multiple-oncology-assets.html#:~:text=ALT%2DB4%20is%20Alteogen's%20proprietary,administered%20as%20an%20IV%20infusion.
56. https://www.bioworld.com/articles/431493-alteogen-licenses-alt-b4-to-a-top-10-global-pharma-in-potential-1b-deal?v=preview
57. https://pharmashots.com/21393/astrazeneca-and-alteogen-enter-an-exclusive-license-deal-for-alt-b4-to-develop-market-subcutaneous-formulations-of-multiple-oncology-drugs
58. https://www.pharmtech.com/view/astrazeneca-alteogen-sign-license-agreement-developing-subcutaneous-formulations-oncology-assets
59. https://pitchbook.com/profiles/company/120447-73#stock
60. https://stockanalysis.com/quote/kosdaq/196170/revenue/
61. https://www.koreabiomed.com/news/articleView.html?idxno=21075
62. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sapablursen
63. https://www.globenewswire.com/news-release/2025/02/20/3029944/0/en/BESREMi-Achieves-Strong-Market-Growth-Amid-Rising-Demand-for-Polycythemia-Vera-Treatment.html
64. https://www.prnewswire.com/news-releases/the-polycythemia-vera-market-landscape-heats-up-amid-rising-competition-among-pharma-companies--delveinsight-302385618.html#:~:text=DelveInsight%20estimates%20that%20the%20market,increased%20awareness%20of%20polycythemia%20vera.
65. https://www.globenewswire.com/news-release/2025/02/20/3029944/0/en/BESREMi-Achieves-Strong-Market-Growth-Amid-Rising-Demand-for-Polycythemia-Vera-Treatment.html
66. https://www.biopharmadive.com/news/ionis-ono-sapablursen-polycythemia-vera-licensing-deal/742269/
67. https://www.techtarget.com/searchcustomerexperience/definition/buzz-marketing#:~:text=By%20getting%20consumers%20talking%20about,and%20increase%20sales%20and%20profits., https://www.shopify.com/ph/blog/buzz-marketing#:~:text=Buzz%20marketing%20can%20help%20your,they'll%20remember%20your%20company.
68. https://clinicaltrials.eu/inn/sapablursen/
69. https://clinicaltrials.eu/inn/sapablursen/#:~:text=What%20Conditions%20Does%20Sapablursen%20Treat?%20Sapablursen%20is,potential%20to%20treat%20two%20main%20blood%20disorders
70. https://www.globenewswire.com/news-release/2025/02/17/3027378/28124/en/Polycythemia-Vera-Market-Insight-Epidemiology-and-Market-Forecast-2034-JAKAFI-BESREMi-Lead-Polycythemia-Vera-Market-But-New-Therapies-Poised-to-Disrupt-by-2034.html
71. https://www.prnewswire.com/news-releases/the-polycythemia-vera-market-landscape-heats-up-amid-rising-competition-among-pharma-companies--delveinsight-302385618.html#:~:text=DelveInsight%20estimates%20that%20the%20market%20size%20for,strategies%2C%20and%20increased%20awareness%20of%20polycythemia%20vera.
72. https://www.biospace.com/press-releases/polycythemia-vera-market-size-to-reach-usd-79-0-billion-by-2035-impelled-by-advancements-in-targeted-therapies#:~:text=The%20Polycythemia%20vera%20market%20reached,13.63%25%20during%202025%2D2035.
73. https://www.statista.com/statistics/796325/ono-pharmaceutical-net-sales/
74. https://www.ono-pharma.com/sites/default/files/en/ir/library/financial_results/2020_fi0512.pdf
75. https://companiesmarketcap.com/inr/ono-pharmaceutical/revenue/
76. https://www.biospace.com/vanda-pharmaceuticals-reports-first-quarter-2020-financial-results#:~:text=Polymeropoulos%2C%20M.D.%2C%20Vanda's%20President%20and%20CEO.&text=Total%20revenues%20from%20HETLIOZ%C2%AE,the%20first%20quarter%20of%202019.
77. https://www.macrotrends.net/stocks/charts/VNDA/vanda-pharmaceuticals/revenue#:~:text=2020%2D12%2D31,$0.047B
78. https://ir.anaptysbio.com/news-releases/news-release-details/vanda-pharmaceuticals-and-anaptys-announce-exclusive-global
79. https://in.investing.com/news/transcripts/earnings-call-vanda-pharmaceuticals-reports-mixed-q3-2024-results-93CH-4515068
80. https://vandapharmaceuticalsinc.gcs-web.com/node/15726/pdf#:~:text=Important%20factors%20that%20could%20cause,at%20www.sec.gov.
81. https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-302056697.html#:~:text=Fourth%20Quarter%20of%202023&text=The%20decrease%20relative%20to%20the,Johnson%20Company%2C%20for%20$100.0%20million.
82. https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-301742439.html
83. https://vandapharmaceuticalsinc.gcs-web.com/node/15726/pdf
84. https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-fourth-quarter-and-full-year-2024-financial/#:~:text=Announced%20an%20exclusive%20global%20out,royalty%20on%20global%20net%20sales
85. https://ir.anaptysbio.com/news-releases/news-release-details/vanda-pharmaceuticals-and-anaptys-announce-exclusive-global/#:~:text=%22Vanda%20is%20an%20ideal%20partner,including%20their%20growing%20presence%20in
86. https://www.anaptysbio.com/#:~:text=We%20are%20a%20clinical%2Dstage,in%20autoimmune%20and%20inflammatory%20diseases.&text=The%20Anaptys%20Difference%20Best%2Din,response%20and%20restore%20immune%20balance.
87. https://www.biospace.com/vanda-pharmaceuticals-reports-first-quarter-2020-financial-results#:~:text=Polymeropoulos%2C%20M.D.%2C%20Vanda's%20President%20and%20CEO.&text=Total%20revenues%20from%20HETLIOZ%C2%AE,the%20first%20quarter%20of%202019.
88. https://www.macrotrends.net/stocks/charts/VNDA/vanda-pharmaceuticals/revenue#:~:text=2020%2D12%2D31,$0.047B
89. https://www.vandapharma.com/pipeline/
90. https://www.biospace.com/press-releases/generalized-pustular-psoriasis-market-size-to-reach-usd-36-9-billion-by-2035-impelled-by-advancements-in-targeted-biologic-therapies
91. https://www.pharmaceutical-technology.com/data-insights/imsidolimab-anaptysbio-net-present-value/
92. https://companiesmarketcap.com/inr/nippon-shinyaku/revenue/
93. https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-and-nippon-shinyaku-announce-exclusive-partnership
94. https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-and-nippon-shinyaku-announce-exclusive-partnership/#:~:text=REGENXBIO%20will%20also%20receive%20meaningful,Representative%20Director%20of%20Nippon%20Shinyaku
95. https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-closing-strategic-partnership-nippon#:~:text=REGENXBIO%20Announces%20Closing%20of%20Strategic%20Partnership%20with%20Nippon%20Shinyaku%20for%20MPS%20Diseases.&text=Under%20the%20terms%20of%20the%20agreement%2C%20REGENXBIO,in%20the%20United%20States%20and%20Asia%20.
96. https://www.biopharmadive.com/news/regenxbio-nippon-shinyaku-gene-therapy-mps-hunter-hurler/737250/
97. https://www.nipponpaint-holdings.com/en/ir/library/materials/20240214_summary/#:~:text=The%20year%2Dover%2Dyear%20revenue,Japanese%20and%20European%20automobile%20manufacturers.
98. https://www.marketscreener.com/quote/stock/NIPPON-SHINYAKU-CO-LTD-6491859/news/Nippon-Shinyaku-Ending-March-2024-FY2023-Presentation-Material-for-IR-Meeting-2Q-FY2023-Script-Q-45517961/
99. https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-and-nippon-shinyaku-announce-exclusive-partnership/#:~:text=Under%20the%20terms%20of%20the,in%20Phase%201/2%20study.
100. https://www.prnewswire.com/news-releases/regenxbio-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-operational-updates-302401438.html#:~:text=Now%20partnered%20with%20Nippon%20Shinyaku%2C%20RGX%2D121%20is,REGENXBIO%20if%20approved%20in%20the%20coming%20months.&text=In%20March%202025%2C%20REGENXBIO%20announced%20the%20successful,I%20in%20the%20United%20States%20and%20Asia.
101. https://www.prnewswire.com/news-releases/mediar-therapeutics-enters-into-global-licensing-agreement-with-lilly-to-advance-first-in-class-wisp1-antibody-for-the-treatment-of-idiopathic-pulmonary-fibrosis-ipf-302347905.html
102. https://www.globenewswire.com/news-release/2025/03/06/3038202/0/en/Idiopathic-Pulmonary-Fibrosis-Market-Size-is-Expected-to-Reach-USD-9-23-Billion-by-2033-Growing-at-a-CAGR-of-7-35-Straits-Research.html
103. https://www.biospace.com/press-releases/mediar-therapeutics-enters-into-global-licensing-agreement-with-lilly-to-advance-first-in-class-wisp1-antibody-for-the-treatment-of-idiopathic-pulmonary-fibrosis-ipf
104. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-strong-fourth-quarter-and-full-year-2020-financial
https://investor.lilly.com/news-releases/news-release-details/lilly-announces-2020-financial-guidance-updates-2019-guidance#:~:text=Earnings%20per%20share%20for%202020,exclude%20amortization%20of%20intangible%20assets.&text=The%20company%20anticipates%202020%20revenue,in%20China%20%2C%20Japan%20and%20Europe%20
105. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-solid-fourth-quarter-and-full-year-2021-financial#:~:text=U.S.%20revenue%20was%20$121.0%20million,primarily%20due%20to%20increased%20demand.&text=For%20the%20fourth%20quarter%20of%202021%2C%20the%20company's%20Tyvyt%20revenue,offset%20by%20lower%20realized%20prices.
106. https://www.lilly.com/policies-reports/2024-year-in-review?redirect-referrer=https%3A%2F%2Fwww.google.com%2F
https://investor.lilly.com/news-releases/news-release-details/lilly-reports-solid-third-quarter-2022-financial-results-and#:~:text=In%20Q3%202022%2C%20worldwide%20revenue,increased%209%25%20in%20Q3%202022.
107. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-strong-fourth-quarter-2023-financial-results-and#:~:text=In%20Q4%202023%2C%20worldwide%20revenue,$5.27%20billion%20in%20Q4%202023.
108. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025
https://investor.lilly.com/news-releases/news-release-details/lilly-provides-update-2024-revenue-guidance-announces-2025#:~:text=2024%20revenue%20is%20expected%20to,20%25%20compared%20to%20Q4%202023.
109. https://www.biospectrumasia.com/company-results/102/25588/eli-lilly-reports-record-q4-2024-revenue-of-13-53b-fueled-by-mounjaro-zepbound-and-oncology-growth.html#:~:text=Eli%20Lilly%20&%20Co.%20reported%20a%20strong,therapeutic%20areas%2C%20including%20oncology%2C%20neuroscience%2C%20and%20immunology.
110. https://www.fiercepharma.com/pharma/while-lilly-and-novos-momentum-stalled-q3-pfizer-moved-top-spot-leading-industry-wide-sales#:~:text=The%20company%20pointed%20out%20that%20its%20Q3,in%20the%20third%20quarter%20of%20last%20year.
111. https://www.lilly.com/policies-reports/2024-year-in-review?redirect-referrer=https%3A%2F%2Fwww.google.com%2F
https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025#:~:text=Revenue%20in%20Q4%202024%20increased,mutant%2Dselective%20PI3K%CE%B1%20inhibitor%20program.
112. https://www.fiercepharma.com/pharma/eli-lillys-very-beatable-2025-guidance-should-ease-investor-sentiment-after-recent-glp-1#:~:text=Zepbound%20%7C%20Fierce%20Pharma-,Eli%20Lilly%20logs%20massive%20Q4%20revenue%20jump%E2%80%94but%20it's%20not,thanks%20to%20Mounjaro%20and%20Zepbound&text=Thanks%20to%20impressive%20sales%20growth,were%20reaching%20a%20sales%20plateau.
113. https://www.prnewswire.com/news-releases/lilly-reports-full-q4-2024-financial-results-and-provides-2025-guidance-302369432.html#:~:text=In%20Q4%202024%2C%20worldwide%20revenue,growth%20from%20Mounjaro%20and%20Zepbound.
114. https://www.prnewswire.com/news-releases/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum-302443401.html#:~:text=%22Lilly%20had%20a%20solid%20start,to%20build%20four%20new%20facilities.%22
115. https://www.prnewswire.com/news-releases/alchemab-therapeutics-enters-into-collaboration-with-lilly-to-discover-research-and-develop-novel-therapies-for-als-302346205.html
116. https://www.biopharmatrend.com/post/1102-eli-lilly-partners-with-uks-alchemab-to-develop-new-als-antibodies/
117. https://manufacturingchemist.com/eli-lilly-alchemab-therapeutics-collaboration-als-antibody-discovery-development#:~:text=develop%20ALS%20antibodies-,Eli%20Lilly%20and%20Alchemab%20Therapeutics%20team%20up%20to%20discover%20and,the%20success%20of%20the%20project.
118. https://www.mewburn.com/news-insights/alchemab-the-art-of-ai-antibody-discovery#:~:text=Alchemab's%20artificial%20intelligence%20platform%20enables%20the%20identification,pharma%2C%20from%20treating%20Alzheimer's%20to%20beating%20cancer.&text=To%20do%20that%2C%20Alchemab%20uses%20AI%20to,who%20have%20succumbed%20to%20the%20particular%20illness.
119. https://www.prnewswire.com/news-releases/alchemab-advances-a-novel-antibody-with-potential-in-parkinsons-disease-with-support-from-the-michael-j-fox-foundation-302165114.html#:~:text=Alchemab's%20platform%20integrates%20data%20mining%20of%20patient%2Dderived,human%20immune%20system%20to%20find%20breakthrough%20drugs.
120. https://www.biospace.com/press-releases/1cbio-and-alesta-therapeutics-announce-exclusive-global-licensing-agreement-for-a-novel-potentially-first-in-class-small-molecule-for-hypophosphatasia
121. https://www.pharmasalmanac.com/articles/1cbio-and-alesta-therapeutics-sign-global-deal-to-develop-a-first-in-class-small-molecule-treatment-for-hypophosphatasia
122. https://www.astrazeneca.com/r-d/next-generation-therapeutics/antibody-drug-conjugate.html#:~:text=Antibody%20drug%20conjugates%20(ADCs)%20are%20targeted%20medicines,via%20a%20linker%20attached%20to%20monoclonal%20antibody.&text=ADCs%20combine%20a%20monoclonal%20antibody%20(mAb)%2C%20which,cytotoxic%20chemotherapy%20agent%2C%20via%20a%20chemical%20linker.
123. https://my.clevelandclinic.org/health/treatments/antibody-drug-conjugates
124. https://www.astrazeneca.com/r-d/next-generation-therapeutics/antibody-drug-conjugate.html#:~:text=Antibody%20drug%20conjugates%20(ADCs)%20are%20targeted%20medicines,via%20a%20linker%20attached%20to%20monoclonal%20antibody.&text=ADCs%20combine%20a%20monoclonal%20antibody%20(mAb)%2C%20which,cytotoxic%20chemotherapy%20agent%2C%20via%20a%20chemical%20linker.
125. https://www.globenewswire.com/news-release/2025/01/22/3013689/0/en/Antibody-Drug-Conjugates-Market-Size-is-Expected-to-Reach-USD-25-38-Billion-by-2033-Growing-at-a-CAGR-of-8-84-Straits-Research.html
126. https://www.biochempeg.com/article/261.html#:~:text=According%20to%20a%20publication%20in%20Nature%20Reviews,its%20potential%20indications%20for%20multiple%20cancer%20types[3].&text=In%202021%2C%20the%20global%20ADC%20market%20exceeded%20$5%20billion.
127. https://www.sciencedirect.com/science/article/abs/pii/B9780128211854000038
128. https://www.biospace.com/antibody-drug-conjugates-market-size-to-reach-usd-28-61-bn-by-2033#:~:text=The%20global%20rise%20in%20cancer,improving%20access%20to%20these%20therapies.&text=The%20North%20America%20antibody%20drug,share%20of%2052.95%25%20in%202023.&text=The%20breast%20cancer%20segment%20dominated,share%20of%2072.95%25%20in%202023.
129. https://www.globenewswire.com/news-release/2025/01/08/3006165/0/en/Araris-Biotech-AG-Announces-Research-Collaboration-and-Option-to-License-Agreement-with-Chugai-Pharmaceutical-Co-to-Develop-Next-Generation-ADCs-Using-Araris-AraLinQ-technology.html
130. https://www.adcreview.com/business-economics/araris-biotech-and-chugai-pharmaceuticals-to-develop-next-generation-tailor-made-adcs/#:~:text=Araris%20Biotech%2C%20a%20spin%2Doff,and%20co%2Dfounder%20of%20Araris.%20,%20https://www.pharmaceutical-technology.com/news/chugai-and-araris-enter-780m-adc-research-collaboration/
131. https://www.psi.ch/en/industry/industry-news/araris-biotech-strategic-partnership-in-the-field-of-cancer-therapy#:~:text=With%20its%20new%20partnership%20with,the%20field%20of%20cancer%20therapy
132. https://www.psi.ch/en/industry/industry-news/araris-biotech-strategic-partnership-in-the-field-of-cancer-therapy
133. https://www.adcreview.com/business-economics/araris-biotech-and-chugai-pharmaceuticals-to-develop-next-generation-tailor-made-adcs/
134. https://www.globenewswire.com/news-release/2025/03/17/3043491/28124/en/Anti-Obesity-Drugs-Market-Industry-Trends-Sales-Forecast-Key-Players-and-Global-Forecasts-to-2035-Semaglutide-Tirzepatide-Lead-the-Global-Anti-Obesity-Drug-Market-Boom.html
135. https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
136. https://globenewswire.com/news-release/2025/03/04/3036644/28124/en/Obesity-7-Major-Market-Research-2025-There-will-be-an-Increase-in-Therapies-with-Longer-Duration-of-Action-Disease-Management-Epidemiology-Pipeline-Analysis-Unmet-Needs-and-Drug-Fo.html
137. https://www.biospace.com/obesity-market-to-reach-150b-as-demand-grows-supply-stabilizes-reuters
138. https://radiologybusiness.com/topics/healthcare-management/mergers-and-acquisitions/lantheus-acquire-radiopharma-firm-evergreen-theragnostics-1b
139. https://www.oncologypipeline.com/apexonco/lantheus-goes-evergreen#:~:text=Lantheus%20has%20been%20busy%20striking,%2Dstage%20diagnostic%20agent%2C%20Octevy
140. https://cen.acs.org/business/mergers-&-acquisitions/Lantheus-buys-radiopharma-CDMO-Evergreen/103/i3#:~:text=Lantheus%2C%20a%20Massachusetts%2Dbased%20developer,%24750%20million%20in%20milestone%20payments.
141. https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-reports-fourth-quarter-and-full-year-2024-financial
142. https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-reports-fourth-quarter-and-full-year-2024-financial
143. https://investor.lantheus.com/news-releases/news-release-details/lantheus-reports-fourth-quarter-and-full-year-2020-financial#:~:text=The%20Company's%20worldwide%20revenue%20for%20the%20fourth,of%202019%2C%20representing%20an%20increase%20of%205.4%
144. https://investor.lantheus.com/news-releases/news-release-details/lantheus-holdings-inc-reports-fourth-quarter-and-full-year-2021#:~:text=The%20Company's%20worldwide%20revenue%20for,quarter%20and%20full%20year%202021.
145. https://investor.lantheus.com/news-releases/news-release-details/lantheus-holdings-inc-reports-fourth-quarter-and-full-year-2021#:~:text=The%20Company's%20worldwide%20revenue%20for,over%20the%20prior%20year%20period.
146. https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-reports-fourth-quarter-and-full-year-2022-financial
147. https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-reports-fourth-quarter-and-full-year-2023-financial
148. https://www.evergreentgn.com/news/rls-and-evergreen-theragnostics-launch-partnership-for-sale-and-distribution-of-neuroendocrine-tumor-diagnostic-octevy-tm-kit-for-preparation-of-ga-68-dotatoc-injection-pending-fda-approval-2
149. https://www.prnewswire.com/news-releases/uppi-and-evergreen-theragnostics-announce-partnership-for-sales-and-distribution-of-octevy-kit-for-preparation-of-ga-68-dotatoc-injection-pending-fda-approval-in-2h-2023-301936550.html
150. https://www.evergreentgn.com/news/uppi-and-evergreen-theragnostics-announce-partnership-for-sales-and-distribution-of-octevy-tm-kit-for-preparation-of-ga-68-dotatoc-injection-pending-fda-approval-in-2h-2023-2#:~:text=%E2%80%8D,centers%20in%20the%20United%20States.
151. https://www.evergreentgn.com/news/jubilant-radiopharma-and-evergreen-theragnostics-launch-collaboration-for-the-sale-and-distribution-of-octevy-tm-kit-for-preparation-of-ga-68-dotatoc-injection-pending-fda-approval-in-2h-2023#:~:text=About%20OCTEVY%E2%84%A2-,OCTEVY%E2%84%A2%20(Kit%20for%20Preparation%20of%20Ga%2068%20DOTATOC%20Injection,About%20Jubilant%20Radiopharmacy%20Business
152. https://investor.lantheus.com/news-releases/news-release-details/lantheus-reports-fourth-quarter-and-full-year-2024-financial
153. https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-completes-acquisition-evergreen-theragnostics
154. https://www.globenewswire.com/news-release/2025/04/01/3053408/0/en/Lantheus-Completes-Acquisition-of-Evergreen-Theragnostics.html
155. https://www.pharmtech.com/view/lantheus-agreement-acquire-evergreen-theragnostics
156. https://www.timothysykes.com/news/lantheus-holdings-inc-lnth-news-2025_02_26-2/
157. https://www.stocktitan.net/news/LNTH/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-myqz7b2wrgdf.html
158. https://www.auntminnie.com/clinical-news/article/15707646/lantheus-posts-revenue-increase-in-q3-2024
159. https://radiologybusiness.com/topics/healthcare-management/mergers-and-acquisitions/lantheus-completes-acquisition-radiopharma-firm-evergreen-theragnostics-1b
160. https://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-and-decoy-therapeutics-announce
161. https://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-merger-partner-decoy-therapeutics
162. https://www.globenewswire.com/news-release/2025/04/16/3062473/0/en/Salarius-Pharmaceuticals-Merger-Partner-Decoy-Therapeutics-Appoints-Renowned-MIT-Professor-Robert-S-Langer-to-its-Scientific-Advisory-Board.html
163. https://www.stocktitan.net/news/SLRX/salarius-pharmaceuticals-and-decoy-therapeutics-announce-definitive-cveozjpf8pim.html#:~:text=Biotech%20M&A%20Expert%20positive,inflection%20point%20within%2012%20months.
164. https://in.investing.com/news/sec-filings/salarius-amends-merger-terms-faces-nasdaq-compliance-issue-93CH-4747682
165. https://salariuspharma.com/
166. https://stockanalysis.com/stocks/slrx/revenue/
167. https://www.wallstreetzen.com/stocks/us/nasdaq/slrx/revenue
168. https://qz.com/salarius-pharmaceuticals-inc-slrx-reports-earnings-1851771705#:~:text=The%20filing%20reports%20that%20Salarius%20has%20not,loss%20of%20$5.6%20million%20for%20the%20year.
169. https://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-reports-fourth-quarter-and-full-year-1#:~:text=This%20reduction%20of%20approximately%20$19.1%20million%20resulted,the%20Company's%20idled%20clinical%20trial%20in%20late
170. https://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-reports-2024-financial-results-and#:~:text=About%20the%20Proposed%20Transaction,at%20www.sec.gov.
171. https://www.stocktitan.net/news/SLRX/salarius-pharmaceuticals-and-decoy-therapeutics-announce-definitive-cveozjpf8pim.html#:~:text=The%20IMP3ACT%E2%84%A2%20platform's%20ability,their%20work%20on%20H5N1%20flu.
172. https://finance.yahoo.com/news/salarius-pharmaceuticals-merger-partner-decoy-120000163.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAIeyTDKUk5iS_xrYc0CXmkswiG982QUbl1E_NCgI2liLfYoqJj_hIGCvldn-uuxz7mD2t7V68K6gsZYYR2r5tY1vpPowEm1pyFTObFA9EC-VHWEK_h2jxaQhzrEpqnYIjPrB90-MeGsdq7aP_jRPeB3w7q5mI4sxEN1io1fIub9u
173. https://in.investing.com/news/sec-filings/salarius-amends-merger-terms-faces-nasdaq-compliance-issue-93CH-4747682
174. https://www.biospace.com/press-releases/salarius-pharmaceuticals-reports-2024-financial-results-and-provides-business-update
175. https://in.investing.com/news/sec-filings/salarius-pharmaceuticals-faces-nasdaq-delisting-over-rule-breaches-93CH-4793147
176. https://www.astrazeneca.com/content/dam/az/PDF/2024/fy/Full-year-and-Q4-2024-results-announcement.pdf
177. https://www.pharmaceutical-technology.com/news/astrazeneca-fy-2021-revenue/
178. https://www.contractpharma.com/top-company-profile/astrazeneca/
179. https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-scorpion-therapeutics-mutant-selective-pi3ka
180. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-strong-fourth-quarter-and-full-year-2020-financial
181. https://investor.lilly.com/static-files/ebc0157d-811b-46fb-82ab-10a1f34d1b2b#:~:text=the%202020%20Annual%20Report%20on%20Form%2010%2DK%20for%20those,pursuant%20to%20Emergency%20Use%20Authorization.&text=Over%20the%20past%20five%20years,price%20and%20increasing%20dividend%20stream.
182. https://www.lilly.com/policies-reports/2024-year-in-review?redirect-referrer=https%3A%2F%2Fwww.google.com%2F
183. https://investor.lilly.com/news-releases/news-release-details/lilly-provides-update-2024-revenue-guidance-announces-2025#:~:text=News%20Release%20*%202024%20revenue%20is%20expected,the%20midpoint%20compared%20to%20expected%202024%20revenue.
184. https://www.lilly.com/policies-reports/2024-year-in-review
185. https://www.businesswire.com/news/home/20201026005156/en/Scorpion-Therapeutics-Launches-with-%24108-Million-to-Advance-Precision-Oncology-2.0
186. https://pitchbook.com/profiles/company/439376-23
187. https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-scorpion-therapeutics-mutant-selective-pi3ka#:~:text=Under%20the%20terms%20of%20the,certain%20regulatory%20and%20sales%20milestones.
188. https://www.biopharmadive.com/news/lilly-pads-cancer-drug-pipeline-with-scorpion-deal/737118/
189. https://ycharts.com/indicators/eli_lilly_and_co_lly_oncology_revenue
190. https://www.prnewswire.com/news-releases/lilly-to-acquire-scorpion-therapeutics-mutant-selective-pi3k-inhibitor-program-302349242.html#:~:text=The%20acquisition%20will%20expand%20Lilly's,as%20well%20as%20improved%20tolerability.
191. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and
192. https://www.expresspharma.in/eli-lilly-to-acquire-scorpion-therapeutics-mutant-selective-pi3ka-inhibitor-program/#:~:text=%E2%80%9CThe%20selectivity%20profile%20of%20STX,holding%20a%20minority%20equity%20interest.
193. https://www.biopharmadive.com/news/lilly-pads-cancer-drug-pipeline-with-scorpion-deal/737118/
194. https://www.blackstone.com/news/press/blackstone-life-sciences-and-anthos-therapeutics-announce-novartis-has-completed-the-acquisition-of-anthos-therapeutics-in-a-deal-valued-at-up-to-3-1b-with-925m-paid-upfront/
195. https://www.blackstone.com/news/press/blackstone-life-sciences-and-anthos-therapeutics-announce-novartis-has-completed-the-acquisition-of-anthos-therapeutics-in-a-deal-valued-at-up-to-3-1b-with-925m-paid-upfront/
196. https://www.novartis.com/sites/novartis_com/files/novartis-annual-report-2020.pdf
197. https://www.fiercepharma.com/special-report/top-20-pharma-companies-by-2020-revenue
198. https://www.novartis.com/sites/novartis_com/files/2022-02-interim-financial-report-en.pdf
199. https://www.novartis.com/investors/financial-data/annual-results
200. https://www.novartis.com/sites/novartis_com/files/q4-2022-media-release-en.pdf
201. https://www.novartis.com/sites/novartis_com/files/q4-2023-media-release-en.pdf#:~:text=Core%20operating%20income%20was%20USD%2016.4%20billion,offset%20by%20higher%20SG&A%20and%20R&D%20investments.&text=Discontinued%20operations%20net%20sales%20in%202023%20were,compared%20to%20USD%201.3%20billion%20in%202022.
202. https://www.statista.com/topics/1828/novartis/#:~:text=In%202023%2C%20Swiss%2Dbased%20Novartis,innovative%20and%20established%20branded%20products.
203. https://www.novartis.com/sites/novartis_com/files/novartis-annual-report-2021.pdf
204. https://www.novartis.com/sites/novartis_com/files/q4-2021-media-release-en.pdf#:~:text=Core%20net%20income%20was%20USD%203.1%20billion,investment%20in%20Rocheand%20a%20higher%20tax%20rate.&text=Generic%20competition%20had%20a%20negative%20impact%20of,due%20to%20Ciprodex%2C%20Afinitor%2C%20Diovan%20and%20Gleevec/Glivec.
205. https://www.novartis.com/news/media-releases/novartis-continues-strong-momentum-double-digit-sales-growth-robust-margin-expansion-and-multiple-approvals-q1#:~:text=Generic%20competition%20had%20a%20negative,cash%20flows%20from%20operating%20activities.
206. https://www.novartis.com/news/media-releases/novartis-continues-strong-momentum-sales-growth-margin-expansion-reaches-key-innovation-milestones-2024
207. https://www.wsj.com/articles/novartis-lifts-dividend-despite-4q-sales-profit-decline-11675233772
208. https://www.pharmexec.com/view/novartis-strikes-deal-acquire-anthos-therapeutics
209. https://www.contractpharma.com/breaking-news/novartis-to-acquire-anthos-therapeutics/#:~:text=Under%20the%20terms%20of%20the,expertise%20in%20the%20cardiovascular%20area.
210. https://www.clinicalresearchnewsonline.com/cln/pressreleases/2025/03/24/novartis-strengthens-cardiovascular-portfolio-with-$3-08-billion-anthos-therapeutics-acquisition#:~:text=Anthos%20Therapeutics%2C%20Inc.%2C%20a,upon%20regulatory%20and%20sales%20milestones.
211. https://investor.endo.com/2020-05-07-Endo-Reports-First-Quarter-2020-Financial-Results-and-Provides-Update-Relating-to-COVID-19-Pandemic
212. https://investor.endo.com/2025-03-13-Endo-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results
213. https://www.prnewswire.com/news-releases/endo-reports-fourth-quarter-and-full-year-2020-financial-results-and-introduces-2021-financial-guidance-301236060.html
214. https://investor.endo.com/2023-03-06-ENDO-REPORTS-FOURTH-QUARTER-2022-FINANCIAL-RESULTS#:~:text=Fourth%2Dquarter%202022%20Sterile%20Injectables%20segment%20revenues%20were,resulting%20from%20generic%20competition%20and%20lower%20overall
215. https://investor.endo.com/2024-03-06-ENDO-REPORTS-FOURTH-QUARTER-2023-FINANCIAL-RESULTS#:~:text=CONSOLIDATED%20FINANCIAL%20RESULTS,primarily%20driven%20by%20decreased%20revenues.
216. https://filecache.investorroom.com/mr5ir_endopharmaceuticals/215/Endo_4Q24_Earnings_Release_FINAL.pdf
217. https://investor.endo.com/2025-05-07-Endo-Reports-First-Quarter-2025-Financial-Results-and-Reaffirms-2025-Financial-Guidance
218. https://investor.endo.com/2024-03-06-ENDO-REPORTS-FOURTH-QUARTER-2023-FINANCIAL-RESULTS#:~:text=CONSOLIDATED%20FINANCIAL%20RESULTS,primarily%20driven%20by%20decreased%20revenues.
219. https://investor.endo.com/2025-03-13-Endo-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results#:~:text=CONSOLIDATED%20RESULTS,SEGMENT%20RESULTS
220. https://www.prnewswire.com/news-releases/endo-reports-fourth-quarter-and-full-year-2024-financial-results-302400716.html
221. https://investor.endo.com/2025-03-13-Endo-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results#:~:text=*%20Endo%20achieved%202024%20revenues%20and%20adjusted,EBITDA%20guidance%20of%20$620%20to%20$650%20million.
222. https://filecache.investorroom.com/mr5ir_endopharmaceuticals/215/Endo_4Q24_Earnings_Release_FINAL.pdf
223. https://investor.endo.com/2025-05-07-Endo-Reports-First-Quarter-2025-Financial-Results-and-Reaffirms-2025-Financial-Guidance#:~:text=CONSOLIDATED%20RESULTS,an%20increase%20in%20interest%20expense.
224. https://investor.endo.com/2020-05-07-Endo-Reports-First-Quarter-2020-Financial-Results-and-Provides-Update-Relating-to-COVID-19-Pandemic
225. https://investor.endo.com/2024-08-27-ENDO-REPORTS-SECOND-QUARTER-2024-FINANCIAL-RESULTS#:~:text=BRANDED%20PHARMACEUTICALS%20SEGMENT,-Branded%20Pharmaceuticals%20segment&text=This%20change%20was%20primarily%20due%20to%20a%20decrease%20in%20SUPPRELIN,increase%20in%20XIAFLEX%C2%AE%20revenues.
226. https://investor.endo.com/2024-05-30-Endo-Provides-Select-First-Quarter-2024-Financial-Results-for-Endo-International-plc#:~:text=EIP%20CONSOLIDATED%20FINANCIAL%20RESULTS&text=Reported%20Net%20Loss%20in%20first,reorganization%20process%20and%20decreased%20revenues.
227. https://investor.endo.com/2025-03-13-Endo-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results
228. https://mallinckrodt.gcs-web.com/news-releases/news-release-details/mallinckrodt-plc-reports-fourth-quarter-and-fiscal-year-2024/#:~:text=Mallinckrodt's%20Specialty%20Generics%20segment%20reported%20net%20sales,of%20high%2Dquality%20products%20amidst%20market%20shortages%20due
229. https://www.prnewswire.com/news-releases/mallinckrodt-plc-reports-fourth-quarter-and-fiscal-year-2024-financial-results-and-provides-2025-guidance-302400719.html
230. https://www.prnewswire.com/news-releases/mallinckrodt-plc-reports-fourth-quarter-and-fiscal-year-2024-financial-results-and-provides-2025-guidance-302400719.html
231. https://mallinckrodt.gcs-web.com/news-releases/news-release-details/mallinckrodt-plc-reports-fourth-quarter-and-fiscal-year-2024/#:~:text=Mallinckrodt's%20Specialty%20Generics%20segment%20reported%20net%20sales,amidst%20market%20shortages%20due%20to%20quality%20and
232. https://ir.mallinckrodt.com/news-releases/news-release-details/mallinckrodt-plc-reports-fourth-quarter-and-fiscal-year-2023/#:~:text=Fiscal%20Year%202023%20Results,2022%20through%20December%2030%2C%202022%20.
233. https://ir.mallinckrodt.com/news-releases/news-release-details/mallinckrodt-plc-reports-fourth-quarter-and-fiscal-2022/#:~:text=Mallinckrodt's%20Adjusted%20EBITDA%20in%20the%20fourth%20quarter,offset%20by%20the%20impact%20from%20cost%20structure
234. https://ir.mallinckrodt.com/news-releases/news-release-details/mallinckrodt-plc-reports-fourth-quarter-and-fiscal-year-2023/#:~:text=Fiscal%20Year%202023%20Results,million%20in%20the%20Successor%20period.
235. https://www.mallinckrodt.com/about/news-and-media/news-detail/?id=31401#:~:text=Fiscal%20Year%202024%20Results1,Adjusted%20EBITDA%20grew%20by%2012.9%25.
236. https://ir.mallinckrodt.com/static-files/2fe0ce2e-8f37-4167-a2b6-079f8a2eeaf7#:~:text=Mallinckrodt's%20fiscal%20year%202024%20performance,Mallinckrodt%20for%20long%2Dterm%20growth.
237. https://investor.endo.com/2025-03-13-Mallinckrodt-and-Endo-to-Combine-to-Create-a-Global,-Scaled,-Diversified-Pharmaceuticals-Leader
238. https://investors.alumis.com/news-releases/news-release-details/alumis-and-acelyrin-announce-amended-merger-agreement
239. https://investors.alumis.com/news-releases/news-release-details/alumis-and-acelyrin-announce-amended-merger-agreement
240. https://www.globenewswire.com/news-release/2025/2/6/3022460/0/en/Alumis-and-ACELYRIN-to-Merge-Creating-a-Late-Stage-Clinical-Biopharma-Company-Dedicated-to-Innovating-Developing-and-Commercializing-Transformative-Therapies-for-Immune-mediated-Di.html
241. https://www.pharmaceutical-technology.com/news/alumis-acelyrin-agreement-merge/?cf-view
242. https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-idrx-inc/#:~:text=GSK%20plc%20(LSE%2FNYSE%3A,gastrointestinal%20stromal%20tumours%20(GIST).
243. https://www.investor.jnj.com/news/news-details/2025/Johnson--Johnson-Closes-Landmark-Intra-Cellular-Therapies-Inc--Acquisition-to-Solidify-Neuroscience-Leadership/default.aspx
244. https://www.contractpharma.com/breaking-news/gsk-acquires-idrx/#:~:text=IDRx's%20lead%20molecule%20IDRX%2D42,gastrointestinal%20stromal%20tumors%20(GIST
245. https://uk.marketscreener.com/quote/stock/BAUSCH-LOMB-CORPORATION-137315071/news/Bausch-Lomb-Corporation-acquired-AcuFocus-Inc-for-35-million-42769085/
246. https://ir.bausch.com/press-releases/bausch-lomb-bolsters-pipeline-acquisition-whitecap-biosciences
247. https://vividion.com/news/vividion-therapeutics-acquires-tavros-therapeutics-to-expand-functional-genomics-capabilities-and-boost-drug-discovery-platform/
248. https://www.businesswire.com/news/home/20250108967074/en/Vividion-Therapeutics-Acquires-Tavros-Therapeutics-to-Expand-Functional-Genomics-Capabilities-and-Boost-Drug-Discovery-Platform
249. https://vividion.com/news/vividion-therapeutics-acquires-tavros-therapeutics-to-expand-functional-genomics-capabilities-and-boost-drug-discovery-platform/
250. https://news.abbvie.com/2025-03-03-AbbVie-and-Gubra-Announce-License-Agreement-to-Develop-an-Amylin-Analog-for-the-Treatment-of-Obesity
251. https://www.kyorin-pharm.co.jp/en/news/docs/KYORIN%20and%20Novartis%20Enter%20into%20a%20Global%20License%20Agreement%20for%20KRP-M223.pdf
252. https://www.fiercebiotech.com/biotech/novartis-inks-preclinical-hives-pact-kyorin-potentially-worth-more-780m
253. https://www.businesswire.com/news/home/20250303601052/en/Gensaic-Announces-Collaboration-with-Novo-Nordisk-to-Unlock-Next-Generation-Precision-Therapies
254. https://www.prnewswire.com/news-releases/magnet-biomedicine-enters-into-a-collaboration-and-license-agreement-with-lilly-to-discover-and-develop-novel-molecular-glue-medicines-302387756.html
255. https://ir.organovo.com/news-releases/news-release-details/organovo-announces-close-sale-fxr-program-eli-lilly-and-company
256. https://www.fiercebiotech.com/biotech/eli-lilly-buys-organovos-fxr-program-10m-sending-biotechs-skyrocketed-244
257. https://www.prnewswire.com/news-releases/bridgene-biosciences-announces-strategic-collaboration-with-takeda-to-discover-small-molecule-drugs-for-immunology-and-neurology-targets-302383673.html
258. https://investors.biogen.com/news-releases/news-release-details/biogen-and-stoke-therapeutics-enter-collaboration-develop-and
259. https://news.abbvie.com/2025-01-23-AbbVie-and-Neomorph-Announce-Collaboration-to-Develop-Molecular-Glue-Degraders-for-Oncology-and-Immunology
260. https://synaffix.com/boehringer-ingelheim-broadens-oncology-portfolio-with-license-for-synaffixs-adc-technology/
261. https://www.fiercebiotech.com/biotech/lonzas-synaffix-adds-boehringer-ingelheim-its-constellation-partners-1b-adc-technology-pact
262. https://www.globenewswire.com/news-release/2025/01/02/3003456/0/en/Atavistik-Bio-Announces-Research-Collaboration-with-Pfizer-to-Accelerate-Discovery-of-Novel-Precision-Allosteric-Therapeutics.html
263. https://www.roche.com/investors/updates/inv-update-2025-03-12
264. https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-acquires-cell-therapy-partner-2seventy-bio-about-286-million-2025-03-11/
265. https://medigene.com/medigene-and-epimab-biotherapeutics-enter-into-a-co-development-partnership-for-tcr-guided-t-cell-engagers/
266. https://investor.incyte.com/news-releases/news-release-details/incyte-and-genesis-therapeutics-announce-strategic-ai-focused
267. https://www.harbourbiomed.com/news/234.html
268. https://www.globenewswire.com/news-release/2025/02/20/3029603/0/en/Photys-Therapeutics-Enters-into-Exclusive-License-Agreement-with-Polymed-for-Phase-1-Ready-IRAK4-Degrader-Furthering-its-Proximity-based-Pipeline-and-Mission.html
269. https://www.globenewswire.com/news-release/2025/02/19/3029076/0/en/Radiance-Biopharma-Enters-Exclusive-License-For-ROR-1-Targeted-Antibody-Drug-Conjugate.html
270. https://www.businesswire.com/news/home/20250212036713/en/ExpressionEdits-Collaborates-with-Boehringer-Ingelheim-to-Develop-Enhanced-Gene-Therapies
271. https://www.businesswire.com/news/home/20250210990350/en/AdvanCell-Enters-Into-Strategic-Collaboration-with-Lilly-to-Advance-Novel-Targeted-Alpha-Therapies-for-the-Treatment-of-Cancer
272. https://www.insideprecisionmedicine.com/topics/precision-medicine/lilly-and-olix-ink-630m-deal-for-early-stage-mash-candidate/
273. https://www.bio-thera.com/plus/view.php?aid=1130
274. https://www.merckgroup.com/en/news/pimicotinib-option-exercise-27-03-25.html
275. https://www.prnewswire.com/news-releases/syneron-bio-announces-strategic-collaboration-with-astrazeneca-302407954.html
276. https://www.globenewswire.com/news-release/2025/03/19/3045140/0/en/Oxford-BioTherapeutics-Enters-into-a-Strategic-Collaboration-with-Roche-to-Discover-Novel-Targets-for-Antibody-Based-Therapeutics-for-the-Treatment-of-Cancer.html
277. https://servier.com/en/newsroom/servier-black-diamond-therapeutics-announce-global-licensing-agreement-bdtx-4933-targeted-oncology-therapy/
278. https://www.globenewswire.com/news-release/2025/03/17/3043727/0/en/Partex-and-Fortress-Biotech-Announce-Strategic-Collaboration-to-Accelerate-Asset-Identification-and-Evaluation-Using-Proprietary-AI-Platform.html
279. https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-enters-strategic-collaboration-hologen-ai-expedite
280. https://www.salipro.com/news/press-release-salipro-biotech-and-boehringer-ingelheim-enter-research-and-license-agreement-to-accelerate-multiple-boehringer-ingelheim-pipeline-programs
281. https://www.globenewswire.com/news-release/2025/02/06/3021891/0/en/Immuneering-Announces-Clinical-Supply-Agreement-with-Regeneron-Pharmaceuticals-to-Evaluate-IMM-1-104-in-Combination-with-Libtayo-cemiplimab.html
282. https://www.grifols.com/en/view-news/-/news/grifols-collaborates-with-startup-fcr-therapeutics-to-develop-recombinant-therapies-for-autoimmune-diseases
283. https://www.orionpharma.com/newsroom/all-news/releases/press-releases/2025/orion-and-invenra-announce-discovery-service-and-commercial-license-agreement-to-develop-innovative-bispecific-antibody-cancer-therapeutics/
284. https://www.globenewswire.com/news-release/2025/01/27/3015292/0/en/AB2-Bio-signs-U-S-option-and-licensing-agreement-with-Nippon-Shinyaku-for-Tadekinig-alfa-for-an-ultra-rare-autoimmune-disease.html
285. https://www.globenewswire.com/news-release/2025/01/22/3013435/0/en/IMMvention-Therapeutix-Enters-Strategic-Collaboration-with-Novo-Nordisk-to-Develop-Oral-Therapies-for-Sickle-Cell-Disease-and-Other-Chronic-Diseases.html
286. https://www.businesswire.com/news/home/20250120534760/en/InnoCare-and-KeyMed-Jointly-Announce-the-License-Agreement-with-Prolium-for-CD20xCD3-Bispecific-Antibody-ICP-B02
287. https://www.rappta-therapeutics.com/rappta-therapeutics-enters-into-a-global-license-agreement-with-springworks-therapeutics-for-a-pre-clinical-first-in-class-molecular-glue-targeting-pp2a/
288. https://news.abbvie.com/2025-01-13-AbbVie-and-Simcere-Zaiming-Announce-Partnership-to-Develop-a-Novel-Trispecific-Antibody-Candidate-in-Multiple-Myeloma
289. https://www.harbourbiomed.com/news/231.html
290. https://www.pharmaceutical-technology.com/news/climb-bio-mabworks-clym116/?cf-view
291. https://www.wuxibiologics.com/press-release/wuxi-biologics-announces-agreement-with-candid-therapeutics-on-trispecific-t-cell-engager/
292. https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-acquire-life-molecular-imaging-upfront-payment-350
293. https://veralox.com/news/veralox-therapeutics-expands-its-pipeline-with-the-exclusive-option-to-acquire-nudge-therapeutics/
294. https://www.globenewswire.com/news-release/2025/04/04/3056001/0/en/Renovaro-Provides-Update-to-Definitive-Agreement-with-Predictive-Oncology.html
295. https://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-merger-partner-decoy-therapeutics
296. https://www.fiercepharma.com/pharma/heels-fda-approval-cancer-drug-sun-pharma-buys-checkpoint-416m
297. https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html
298. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-completes-acquisition-chimerix
299. https://www.biospace.com/business/roche-buys-poseida-for-up-to-1-5b-leaning-into-off-the-shelf-car-t
300. https://investors.lexpharma.com/news-releases/news-release-details/lexicon-pharmaceuticals-announces-exclusive-license-agreement
301. https://www.merck.com/news/merck-enters-exclusive-license-agreement-for-hrs-5346-an-investigational-oral-lipoproteina-inhibitor-for-cardiovascular-disease-from-jiangsu-hengrui-pharmaceuticals-co-ltd/
302. https://www.globenewswire.com/news-release/2025/03/24/3047656/0/en/The-United-Laboratories-and-Novo-Nordisk-announce-exclusive-license-agreement-for-UBT251-a-GLP-1-GIP-glucagon-triple-receptor-agonist.html
303. https://www.harbourbiomed.com/news/239.html
304. https://www.sanofi.com/en/media-room/press-releases/2025/2025-03-20-06-00-00-3045945
305. https://www.cphi-online.com/novel-hyaluronidase-alt-b4-hybrozyme-prod1291523.html
306. https://www.alteogen.com/product_1/?ckattempt=1
307. https://www.nasdaq.com/articles/alteogen-enters-license-deal-daiichi-sankyo-alt-b4-subcutaneous-enhertu-development
308. https://www.nasdaq.com/articles/alteogen-enters-license-deal-daiichi-sankyo-alt-b4-subcutaneous-enhertu-development#:~:text=(RTTNews)%20%2D%20Alteogen%20Inc.%20said%20that%20it,novel%20hyaluronidase%20utilizing%20Hybrozyme%20Technology%2C%20to%20deve.
309. https://www.echemi.com/cms/2281912.html#:~:text=To%20develop%20this%20new%20product,strong%20foundation%20for%20its%20claims.
310. https://www.pharmaceutical-technology.com/news/alteogen-license-deal-sandoz/#:~:text=Sandoz%20will%20have%20global%20rights,version%20of%20a%20biosimilar%20product.&text=Alteogen%20will%20handle%20the%20regulatory,of%20its%20hyaluronidase%20to%20Sandoz.
311. https://dealforma.com/ma-in-biopharma-therapeutics-platforms-q2-2023/#:~:text=Biopharma%20M&A%20activity%20in%20Q2%202023%20picked%20up%20as%20the,billion%20when%20counting%20contingent%20payments.
312. https://www.grantthornton.in/press-room/healthcare-and-pharma-sector-sees-surge-in-high-value-deals-report/#:~:text=The%20pharma%20and%20healthcare%20sector,M&A%20space%20during%20the%20quarter.
313. https://www.pharmaceutical-technology.com/data-insights/global-ma-activity-pharmaceutical-industry/
314. https://www.grantthornton.in/globalassets/1.-member-firms/india/assets/pdfs/dealtracker/pharma_and_healthcare_dealtracker_q2_2024.pdf
315. https://www.business-standard.com/industry/news/pharma-and-healthcare-sector-seals-4-1-bn-deals-in-q2-2024-report-124071600992_1.html
316. https://www.pwc.in/assets/pdfs/deals-at-a-glance-annual-review-2024-v1.pdf
317. https://www.business-standard.com/industry/news/pharma-and-healthcare-sector-seals-4-1-bn-deals-in-q2-2024-report-124071600992_1.html
318. https://drug-dev.com/biopharmaceutical-mega-ma-deals-surge-by-71-yoy-during-q1-2024/#:~:text=Market%20News%20&%20Trends-,Biopharmaceutical%20Mega%20M&A%20Deals%20Surge%20by%2071%25%20YoY%20During%20Q1,leading%20data%20and%20analytics%20company.
319. https://www.fiercebiotech.com/biotech/biopharma-ma-more-doubled-first-quarter-compared-year-prior#:~:text=A%20new%20report%20from%20Leerink%20Partners%20released,six%20in%20the%20first%20quarter%20of%202023.
320. https://www.mmm-online.com/home/channel/biopharma-mampa-activity-jumped-in-q1-2024/
321. https://www.pharmaceutical-technology.com/data-insights/global-ma-activity-pharmaceutical-industry/?cf-view
322. https://www.evaluate.com/blog/2024-dealmaking-whats-the-score/
323. https://drug-dev.com/biopharmaceutical-mega-ma-deals-surge-by-71-yoy-during-q1-2024/#:~:text=Biopharmaceutical%20Mega%20M&A%20Deals%20Surge,the%20pharmaceutical%20industry%20in%202024.
324. https://www.grantthornton.in/globalassets/1.-member-firms/india/assets/pdfs/dealtracker/pharma-and-healthcare-q1-2024-dealtracker.pdf
325. https://www.ey.com/en_cz/insights/strategy-transactions/m-and-a-barometer-cee-third-quarter-2024#:~:text=CEE%20M&A%20activity%20in%20Q3%202024%20saw,despite%20economic%20challenges%20and%20slowing%20deal%20values.&text=M&A%20transactions%20slowed%20in%20Q3%20of%202024%2C,compared%20with%20the%20same%20period%20last%20year.
326. https://www.ey.com/content/dam/ey-unified-site/ey-com/en-gl/insights/life-sciences/documents/ey-gl-pharma-licensing-of-the-future-digital-12-2024.pdf#:~:text=Having%20analyzed%20more%20than%204%2C000%20life%20sciences,and%202021%2C%20reaching%20a%20CAGR%20of%2013%.&text=While%20in%202017%20approximately%20171%20out%20of,than%20261%20out%20of%20747%20in%202022.
327. https://baipharm.chemlinked.com/news/2022s-top-10-cross-border-licensing-deals-involving-chinese-biopharma-companies#:~:text=From%202021%20to%202022%2C%20the,less%20financing%20for%20biopharmaceutical%20companies.
328. https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-biopharma-deck-q1-final.pdf
329. https://www.ropesgray.com/en/insights/alerts/2025/02/key-takeaways-from-the-life-sciences-industry-in-2024-and-whats-next
330. https://pharma-dept.gov.in/sites/default/files/CRO%20Market%20Report_High%20Resolution.pdf#:~:text=The%20Pharmaceutical%20global%20contract%20outsourcing%20market%20has%20been%20picking%20up%20after%20the%20covid%20pandemic.&text=Some%20of%20the%20examples%20include%20IQVIA's%20AI%2Dbased,to%20apply%20AI%20for%20high%2Dthroughput%20molecular%20testing.
331. https://www.mckinsey.com/featured-insights/sustainable-inclusive-growth/charts/pharmas-rx-for-r-and-d
332. https://www.pharmavoice.com/news/pharma-rd-clinical-trial-iqvia-research/747054/#:~:text=A%20drop%20in%20R&D%20deals,deals%20with%20larger%20companies.
333. https://www.statista.com/statistics/965888/number-biotechnology-pharmaceutical-manda-deals/#:~:text=Number%20of%20M&A%20transactions%20in%20biotechnology%20and%20pharmaceuticals%20sector%201985%2D2022&text=Merger%20and%20acquisition%20activity%20was,biorechnology%20and%20pharmaceutical%20sector%20worldwide.
334. https://www.pharmexec.com/view/the-resilience-of-r-d-pharma-posted-record-output-in-2021
335. https://www.pharmaceutical-technology.com/analyst-comment/large-pharma-drug-licensing-china-2024/
336. https://www.pharmexec.com/view/2024-pharm-exec-top-50-companies
337. https://www.fiercebiotech.com/special-reports/top-10-pharma-rd-budgets-2024?itm_source=parsely-api
338. https://www.sciencedirect.com/science/article/pii/S135964462400285X#:~:text=Our%20analysis%20revealed%20that%20despite%20recent%20stabilization%2C,sustained%20turnaround%20in%20R&D%20efficiency%20remains%20elusive.&text=The%20incremental%20decline%20in%20R&D%20productivity%20appears,driven%20largely%20by%20increasing%20late%2Dstage%20clinical%20attrition.
339. https://www.techtarget.com/pharmalifesciences/news/366621118/Pharma-RD-returns-improve-amid-rising-costs-competition#:~:text=Rising%20R&D%20costs&text=The%20industry%20is%20investing%20more,drug%20discovery%20and%20development%20process.
340. https://viseven.com/pharmaceutical-industry-challenges/
341. https://www.contractpharma.com/2023-the-year-of-re-alignment-yet-all-data-points-967523/#:~:text=Emerging%20pharma%20companies%20are%20reassessing,robust%20opportunity%20for%20IPO%20exits.
342. https://news.cision.com/h--lundbeck-a-s/r/lundbeck-completes-acquisition-of-longboard,c4074636
343. http://chemanager-online.com/en/news/eli-lilly-completes-acquisition-of-morphic#:~:text=Eli%20Lilly%20has%20completed%20its,the%20companies%20in%20July%202024.
344. https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-announces-partnership-with-merck-kgaa-darmstadt-germany/#:~:text=Under%20the%20terms%20of%20the,billion%20along%20with%20tiered%20royalties.
345. https://www.novartis.com/news/media-releases/novartis-acquire-regulus-therapeutics-and-farabursen-investigational-microrna-inhibitor-treat-adpkd-most-common-genetic-cause-renal-failure
346. https://www.novartis.com/sites/novartiscom/files/q4-2020-media-release-en.pdf
347. https://www.novartis.com/sites/novartiscom/files/novartis-annual-review-2020-en.pdf
348. https://www.novartis.com/investors/financial-data/annual-results
349. https://www.macrotrends.net/stocks/charts/NVS/novartis-ag/revenue#:~:text=Novartis%20AG%20Revenue%202010%2D2025%20%7C%20NVS%20*,was%20$43.461B%2C%20a%2017.81%%20decline%20from%202021.
350. https://www.novartis.com/news/media-releases/novartis-continues-strong-momentum-sales-growth-margin-expansion-reaches-key-innovation-milestones-2024#:~:text=USD%203.6%20billion.-,Full%20year,amounted%20to%20USD%2016.3%20billion.
351. https://www.pharmaceutical-technology.com/news/novartis-fy2023-net-income/#:~:text=Core%20net%20income%20followed%20suit,$42.2bn%20in%20FY%202022.
352. https://www.macrotrends.net/stocks/charts/NVS/novartis-ag/revenue#:~:text=Novartis%20AG%20annual%20revenue%20for%202023%20was%20$46.66B%2C%20a,a%2017.81%25%20decline%20from%202021.
353. https://ir.regulusrx.com/2025-05-08-Regulus-Therapeutics-Reports-First-Quarter-2025-Financial-Results-and-Recent-Updates#:~:text=On%20April%2030%2C%202025%2C%20the,of%20Directors%20of%20both%20companies.
354. https://www.fiercebiotech.com/biotech/novartis-pays-800m-buy-regulus-phase-3-ready-kidney-drug
355. https://www.prnewswire.com/news-releases/regulus-therapeutics-reports-first-quarter-2025-financial-results-and-recent-updates-302449287.html#:~:text=Share%20this%20article,dominant%20polycystic%20kidney%20disease%20(ADPKD)
356. https://www.novartis.com/news/media-releases/novartis-acquire-regulus-therapeutics-and-farabursen-investigational-microrna-inhibitor-treat-adpkd-most-common-genetic-cause-renal-failure
357. https://www.pharmexec.com/view/novartis-acquire-regulus-therapeutics#:~:text=After%20announcing%20successful%20trial%20results,to%20be%20acquired%20by%20Novartis.&text=This%20will%20add%20the%20potential,of%20treatments%20for%20renal%20disease.
358. https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-buy-regulus-therapeutics-up-17-billion-2025-04-30/#:~:text=The%20deal%2C%20expected%20to%20bolster,treat%20a%20rare%20kidney%20disease.
359. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-completes-acquisition-chimerix
360. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2021
361. https://www.macrotrends.net/stocks/charts/JAZZ/jazz-pharmaceuticals/revenue
362. https://www.genengnews.com/topics/cancer/jazz-to-acquire-chimerix-for-935m-expanding-rare-oncology-portfolio/
363. https://www.contractpharma.com/breaking-news/intas-pharmaceuticals-acquires-udenyca-business-from-coherus-biosciences/
364. https://www.vccircle.com/chryscapitalbacked-intas-pharma-strikes-another-overseas-acquisition
365. https://www.fortuneindia.com/rankings/fortune-500/2021
366. https://www.intaspharma.com/financials/
367. https://www.icra.in/Rating/GetRationalReportFilePdf?id=130936
368. https://www.bwhealthcareworld.com/article/india-pharmaceutical-market-reports-75-yoy-revenue-growth-in-march-2025-553428#:~:text=India%20Pharmaceutical%20Market%20Reports%207.5%25%20YoY%20Revenue%20Growth%20In%20March%202025,-BW%20Online%20Bureau&text=India's%20pharmaceutical%20market%20(IPM)%20recorded,Research%20(Ind%2DRa).
369. https://www.contractpharma.com/breaking-news/intas-pharmaceuticals-acquires-udenyca-business-from-coherus-biosciences/
370. https://www.bioprocessintl.com/deal-making/intas-acquires-udenyca-from-coherus-biosciences-in-potential-558-million-deal
371. https://www.americanpharmaceuticalreview.com/1315-News/618801-Accord-BioPharma-Expands-Biosimilar-Portfolio-with-UDENYCA-Acquisition/#:~:text=%22The%20completion%20of%20the%20UDENYCA,Sign%20up%20now!
372. https://www.nature.com/biopharmdeal